Quantcast

Latest Merck Research Laboratories Stories

2015-04-24 08:30:14

As well as results from its Pivotal Phase 3 C-EDGE Programme Evaluating Grazoprevir/Elbasvir Showing High Sustained Virologic Responses Across Broad Range of Patients with Chronic Hepatitis C Virus

2015-04-19 12:22:28

Pembrolizumab Demonstrated 28 Percent Overall Response Rate and 76 Percent Disease Control Rate in Difficult-to-Treat Cancer First Findings from KEYNOTE-028, Merck's Innovative

2015-04-19 08:21:20

Data from KEYNOTE-006 Study Presented at AACR Annual Meeting and Published in the New England Journal of Medicine KIRKLAND, QC, April 19, 2015 /CNW Telbec/ - Merck (NYSE: MRK),

2015-04-19 08:21:14

KIRKLAND, QC, April 19, 2015 /CNW Telbec/ - Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced new data from KEYNOTE-001, a Phase 1b study evaluating pembrolizumab,

2015-01-26 23:01:38

SITC-Merck Cancer Immunotherapy Clinical Fellowship Award to Grant Young Investigator $100,000 to Advance the Field Milwaukee, WI (PRWEB) January 26, 2015

2014-12-06 12:21:53

Overall Response Rate of 66 Percent Observed in Pembrolizumab-treated Patients Whose Cancer Progressed on Brentuximab Vedotin Phase 2 Study Planned for the First Half of 2015

2014-06-23 20:21:23

Agreement to fund development of compounds for cognitive impairment associated with Alzheimer's disease and other conditions of the central nervous system SAN DIEGO,

2014-06-02 08:31:38

CAMBRIDGE, Mass., June 2, 2014 /PRNewswire/ -- Seres Health, a clinical-stage therapeutics company developing novel products to treat a host of disease conditions based on scientific findings


Word of the Day
dipsas
  • A serpent whose bite was fabled to produce intense thirst.
The word 'dipsas' comes from a Greek word meaning 'thirst'.